Formulation and Drug Delivery

Dalton Receives Funding for Development of RSV and Parainfluenza Type 3 Vaccines

December 01, 2014

Dalton Pharma Services announced it was awarded funding from ISTPCanada for its project to develop vaccines for respiratory syncytial virus and parainfluenza type 3.

PTSM: Pharmaceutical Technology Sourcing and Management

Generic Drugs Face New Regulatory Future

December 01, 2014

Manufacturers face regulatory overhaul, while brand-generic debates escalate over biosimilars and labeling changes.

Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator

November 26, 2014

Opdivo and investigational agent FPA008 will be tested in combination for their efficacy in boosting antitumor immune response.

Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine

November 25, 2014

Merck announced an agreement with NewLink Genetics to acquire exclusive rights to its experimental Ebola vaccine, rVSV-EBOV, for $50 million.

IMS: Global Spending on Medicines to Rise 30% by 2018

November 24, 2014

Approximately 40% of total global growth will come from specialty medications, according to a new report from the IMS Institute for Healthcare Informatics.

FDA Requests Comments on Generic Drug Submission Criteria

November 20, 2014

FDA opens public docket on proposed criteria for “first generic” ANDAs.

GPhA Issues Statement on Generic Drug Costs

November 20, 2014

Ralph G. Neas, president and CEO of the Generic Pharmaceutical Association, requests that Congress get involved in the support of a more competitive drug market.

FDA Practices Discourage Biologic Market Competition, Says PCMA White Paper

November 19, 2014

A new report from The Pharmaceutical Care Management Association alleges that FDA hinders competition in the pharmaceutical industry and influences how a drug's price is calculated.

Pfizer and Merck KGaA Announce Strategic Alliance

November 17, 2014

Pfizer will pay $850 million upfront and as much as $2 billion later in a deal to jointly develop one of Merck?s cancer drugs.

Roche's Avastin Gains Ovarian Cancer Indication

November 17, 2014

Avastin plus chemotherapy for the treatment of ovarian cancer increased progression-free survival by 62% compared with chemotherapy alone.